Video

Our team behind the scenes at SXSW | Opening by Joanna Shields, BenevolentAI CEO

In our 5 part series filmed at SXSW, our team showcased how AI can be used to better understand the underlying causes of disease, and redefine the way new medicines are brought to patients.

In this first video, our CEO, Joanna Shields, introduces the Benevolent team and our vision. We brought our Benevolent Team to Texas to share our collective vision of using the power of technology to solve something that truly matters to the world. For us, this means tackling the most challenging and devastating diseases that currently have no cure. We believe our efforts can and will change outcomes for patients.

There are an estimated 9,000 untreated diseases in the world and 300 million people suffering from rare diseases. Developing a treatment and getting it to market takes 10-15 years and costs more than $2.5 billion. After all that, the top ten selling drugs in the market today only work for 30-50% of patients.

Why? Because biology is complicated. The underlying molecular mechanisms, pathways and biological processes specific to a patient needs to be fully understood to effectively diagnose a disease and develop a medicine to treat it.

Humans are limited by the amount of information they can absorb and process. Against a backdrop of >10,000 new scientific papers published daily, and the millions of patents, chemical databases, clinical trials and countless other data sources, it’s almost impossible for scientists to leverage all the existing information to make new discoveries.  While this deluge of data represents a limitation of human comprehension, it lends itself perfectly to machine learning.  

AI can help us uncover relationships between diseases and symptoms, drugs and their effect, the patients that will best respond to treatment and much more. At BenevolentAI, we believe that unconventional thinking combined with purposeful technology can truly make an impact on humanity.  

Watch our team share this example of how we work to do exactly that.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022